title: Adenosine negatively regulates duodenal motility in mice: role of A(1)  and A(2A)  receptors.
abstract: OBJECTIVE
  Adenosine is considered to be an important modulator of intestinal motility. This study was undertaken to investigate the role of adenosine in the modulation of contractility in the mouse duodenum and to characterize the adenosine receptor subtypes involved.
  
  
  METHODS
  RT-PCR was used to investigate the expression of mRNA encoding for A(1), A(2A), A(2B) and A(3) receptors. Contractile activity was examined in vitro as changes in isometric tension.
  
  
  RESULTS
  In mouse duodenum, all four classes of adenosine receptors were expressed, with the A(2B) receptor subtype being confined to the mucosal layer. Adenosine caused relaxation of mouse longitudinal duodenal muscle; this was antagonized by the A(1) receptor antagonist and mimicked by N(6) -cyclopentyladenosine (CPA), selective A(1) agonist. The relaxation induced by A(1) receptor activation was insensitive to tetrodotoxin (TTX) or N(ω) -nitro-l-arginine methyl ester (l-NAME). Adenosine also inhibited cholinergic contractions evoked by neural stimulation, effect reversed by the A(1) receptor antagonist, but not myogenic contractions induced by carbachol. CPA and 2-p-(2-carboxyethyl) phenethylamino-5'-N-ethylcarboxamidoadenosine hydrochloride hydrate (CGS-21680), A(2A) receptor agonist, both inhibited the nerve-evoked cholinergic contractions. l-NAME prevented only the CGS-21680-induced effects. S-(4-Nitrobenzyl)-6-thioinosine, a nucleoside uptake inhibitor, reduced the amplitude of nerve-evoked cholinergic contractions, an effect reversed by an A(2A) receptor antagonist or l-NAME.
  
  
  CONCLUSIONS
  Adenosine can negatively regulate mouse duodenal motility either by activating A(1) inhibitory receptors located post-junctionally or controlling neurotransmitter release via A(1) or A(2A) receptors. Both receptors are available for pharmacological recruitment, even if only A(2A) receptors appear to be preferentially stimulated by endogenous adenosine.
authors: Dipartimento di Scienze e Tecnologie Molecolari e Biomolecolari (STEMBIO), Laboratorio di Fisiologia Generale, Università di Palermo, Palermo, Italy.
authors: M G
authors: MG
authors: Zizzo
authors: M
authors: M
authors: Mastropaolo
authors: L
authors: L
authors: Lentini
authors: F
authors: F
authors: Mulè
authors: R
authors: R
authors: Serio
references: Br J Pharmacol. 2003 Apr;138(7):1333-9
references: 12711634
references: Br J Pharmacol. 1999 Mar;126(5):1269-75
references: 10205018
references: Acta Physiol Scand. 1985 Feb;123(2):195-203
references: 2984897
references: Br J Pharmacol. 1992 Mar;105(3):639-42
references: 1628151
references: Eur J Pharmacol. 1985 Jul 31;113(3):417-24
references: 4043215
references: Br J Pharmacol. 2009 Nov;158 Suppl 1:S1-254
references: 19883461
references: Neuroscience. 1998 Jan;82(2):623-9
references: 9466466
references: J Auton Pharmacol. 2001 Feb;21(1):29-38
references: 11422576
references: Inflamm Bowel Dis. 2008 Apr;14(4):566-74
references: 18022872
references: Am J Physiol. 1992 Mar;262(3 Pt 1):G525-31
references: 1372485
references: Eur J Pharmacol. 2004 Jul 8;495(1):1-16
references: 15219815
references: Life Sci. 2009 May 22;84(21-22):772-8
references: 19324061
references: J Comp Neurol. 2001 Oct 8;439(1):46-64
references: 11579381
references: Pharmacol Rev. 2001 Dec;53(4):527-52
references: 11734617
references: Jpn J Pharmacol. 1995 Dec;69(4):429-33
references: 8786647
references: Inflamm Bowel Dis. 2006 Feb;12(2):117-22
references: 16432376
references: Eur J Pharmacol. 2003 Jan 24;460(2-3):183-90
references: 12559380
references: Br J Pharmacol. 2009 Sep;158(1):243-51
references: 19466981
references: Can J Physiol Pharmacol. 2005 Aug-Sep;83(8-9):805-10
references: 16333383
references: Neuroscience. 1995 Jul;67(1):159-68
references: 7477896
references: Am J Physiol Gastrointest Liver Physiol. 2002 Nov;283(5):G1132-8
references: 12381527
references: FEBS J. 2009 Jan;276(2):318-29
references: 19076212
references: J Pharmacol Exp Ther. 1990 Apr;253(1):290-5
references: 1691784
references: Eur J Pharmacol. 1990 Jul 17;182(3):487-95
references: 1977591
references: Br J Pharmacol. 2003 May;139(1):172-84
references: 12746236
references: J Biol Chem. 1995 Feb 3;270(5):2387-94
references: 7836474
references: Br J Pharmacol. 2010 Oct;161(4):856-71
references: 20860664
references: Br J Pharmacol. 2009 Feb;156(3):519-33
references: 19154428
references: Br J Pharmacol. 1996 Aug;118(8):2073-8
references: 8864545
references: Eur J Pharmacol. 2011 Jan 15;650(2-3):639-49
references: 21034735
references: Eur J Pharmacol. 2008 Mar 17;582(1-3):132-8
references: 18234188
references: Eur J Pharmacol. 2005 Oct 3;521(1-3):133-8
references: 16185686
references: FASEB J. 2009 Aug;23(8):2727-34
references: 19357134
references: Eur J Pharmacol. 1997 Nov 5;338(2):143-50
references: 9455996
references: Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):364-74
references: 11111830
references: Br J Pharmacol. 1996 Jan;117(1):170-4
references: 8825359
references: Br J Pharmacol. 2006 Aug;148(7):956-63
references: 16847444
references: Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):382-91
references: 11111832
references: Br J Pharmacol. 2004 Mar;141(6):925-34
references: 14993098
references: Eur J Pharmacol. 2000 Dec 15;409(3):319-23
references: 11108827
references: Purinergic Signal. 2008 Jun;4(2):89-92
references: 18368529
references: Neurochem Int. 2004 Oct;45(5):641-51
references: 15234106
references: Pharmacol Rev. 1994 Jun;46(2):143-56
references: 7938164
references: Neurogastroenterol Motil. 2009 Apr;21(4):451-66
references: 19019012
references: BMC Neurosci. 2002 Dec 20;3:21
references: 12495441
references: Pharmacol Ther. 2008 Dec;120(3):233-53
references: 18848843